The Latest in Outcomes
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted in the 2025 ASH Annual Meeting plenary session
Read Press Release
The Latest in Outcomes
eGenesis Announces Another New Hampshire Man Gets a Pig Kidney as Transplant Trials Are Poised to Start
eGenesis Announces Another New Hampshire Man Gets a Pig Kidney as Transplant Trials Are Poised to Start
Read Press Release
The Latest in Outcomes
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia
A clinical-stage biotechnology company focused on developing next-generation precision medicines
Read Press Release
The Latest in Outcomes
Variant Bio Turns Toward Discovery of Novel Medicines, Marking a New Chapter of Growth for the Company
Variant Bio Turns Toward Discovery of Novel Medicines
Read Press Release
The Latest in Outcomes
Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems
Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells
Read Press Release
The Latest in Outcomes
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial
Read Press Release
The Latest in Outcomes
Gene-Edited Pig Kidney Xenotransplants Get IND Clearance for Clinical Trials
Gene-Edited Pig Kidney Xenotransplants Get IND Clearance for Clinical Trials
Read Press Release Empowering the Next Generation of Healthcare
The healthcare sector has reached an inflection point. Technology and innovation are allowing the integration of physicians, payers, and patients to provide better outcomes and challenge the status quo. At Alta, we believe healthcare ultimately should work for patients. We are dedicated to helping entrepreneurs build high-impact companies.
Choose an option below to login.